Agios Pharmaceuticals:适应症叠加正在打造商业飞轮(纳斯达克:AGIO)
· seekingalpha.com
Agios正在利用mitapivat(Pyrukynd)治疗丙酮酸激酶缺乏症、地中海贫血和镰状细胞病,打造罕见病特许经营权。在此阅读更多关于AGIO股票的信息。
In my view, the market appears focused on Agios Pharmaceuticals, Inc.'s ( AGIO ) continued net losses, as well as the discontinuation of tebapivat development a...